Drug Trial Radar · NCT03767244
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,517
Actual
Start
Jun 11, 2019
Primary completion
Dec 1, 2026
Study completion Oct 13, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS) as compared to placebo plus ADT.
Conditions
- Prostatic Neoplasms
Interventions
ApalutamideDrug
Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.
Androgen Deprivation Therapy (ADT)Drug
Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter \[ng/dL\]).
PlaceboDrug
Participants will receive matching placebo oral tablets daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Pathologic complete response (pCR)Time frame: Approximately 4 years
- Metastasis-Free Survival (MFS)Time frame: Up to 7 years and 5 months
Locations
203 sites in 18 countries. Site status is shown where the registry gives one.
UC San Diego Moores Cancer Center
La Jolla, California
University of Southern California
Los Angeles, California
Cedars Sinai Medical Center
Los Angeles, California
University of California Los Angeles
Los Angeles, California
University of California Irvine Medical Center Chao Family Comprehensive Cancer Center
Orange, California
UC Davis Medical Center
Sacramento, California
AdventHealth Medical Group Urology of Denver
Denver, Colorado
Colorado Clinical Research
Lakewood, Colorado
Stamford Hospital
Stamford, Connecticut
Urology Specialists LLC
Hialeah, Florida
Mayo Clinic - Division Of Hematology/oncology
Jacksonville, Florida
Miami Cancer Institute at Baptist Health / Baptist Health Medical Group
Miami, Florida
Advent Health
Orlando, Florida
Emory University Winship Cancer Institute
Atlanta, Georgia
University of Chicago
Chicago, Illinois
Ochsner LSU Health Shreveport - Regional Urology
Shreveport, Louisiana
Dana Farber Cancer Institute
Boston, Massachusetts
Beth Isreal Deaconess Medical Center
Boston, Massachusetts
Michigan Institute of Urology, PC
Troy, Michigan
Saint Louis University
St Louis, Missouri
Urology Cancer Center, PC
Omaha, Nebraska
Albany Medical College
Albany, New York
Great Lakes Physician PC d/b/a Western New York Urology Associates
Cheektowaga, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Weill Cornell Medical College
New York, New York
SUNY Upstate Medical University
Syracuse, New York
University of North Carolina
Chapel Hill, North Carolina
Duke University School of Medicine
Durham, North Carolina
Medication Management LLC
Greensboro, North Carolina
Carolina Urology Partners, PLLC
Huntersville, North Carolina
Cleveland VA Medical Center
Cleveland, Ohio
Oklahoma City VAMC
Oklahoma City, Oklahoma
MidLantic Urology
Bala-Cynwyd, Pennsylvania
Omega Medical Research
Warwick, Rhode Island
Ralph H. Johnson Veterans Affairs Medical Center
Charleston, South Carolina
Medical University of South Carolina
Charleston, South Carolina
Greenville Health
Greenville, South Carolina
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
VA North Texas Health Care System
Dallas, Texas
Showing 40 of 203 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.